296 - Therapeutic Approaches to Hidden Hearing Loss with Celia Belline, CEO of Cilcare

What if we could treat hearing loss before it shows up on a standard audiogram? Celia Belline, CEO and co-founder of Cilcare, shares progress on the company’s lead compound, CIL001, developed to treat cochlear synaptopathy—often referred to as hidden hearing loss.A Phase 2A clinical trial is planned to begin later this year, targeting individuals with type 2 diabetes who are more likely to present early signs of the condition.The conversation explores how early-stage auditory synaptic damage may contribute to both hearing difficulties in noise and tinnitus, why timely intervention matters, and what’s ahead for the hearing therapeutics field.🔗 Learn more: https://www.cilcare.comBe sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn, Instagram and X.- https://x.com/WeekinHearing- https://www.instagram.com/thisweekinhearing/- https://www.linkedin.com/company/this-week-in-hearing- https://hearinghealthmatters.org/thisweek/